MALCOLM BRENNER to Receptors, Antigen, T-Cell
This is a "connection" page, showing publications MALCOLM BRENNER has written about Receptors, Antigen, T-Cell.
Connection Strength
7.558
-
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820.
Score: 0.551
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.439
-
Next Steps in the CAR Journey of a Thousand Miles. Mol Ther. 2017 10 04; 25(10):2226-2227.
Score: 0.436
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.429
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.427
-
CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
Score: 0.377
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
Score: 0.372
-
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan; 257(1):107-26.
Score: 0.337
-
CAR T cells for acute myeloid leukemia: the LeY of the land. Mol Ther. 2013 Nov; 21(11):1983-4.
Score: 0.333
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.288
-
T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1.
Score: 0.261
-
Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
Score: 0.257
-
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006 Oct; 20(10):1819-28.
Score: 0.202
-
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.
Score: 0.182
-
Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003; 110(2-3):154-9.
Score: 0.157
-
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16.
Score: 0.149
-
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001 Oct 15; 94(2):228-36.
Score: 0.144
-
Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells. J Immunother Cancer. 2020 11; 8(2).
Score: 0.135
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.132
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.125
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.117
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194.
Score: 0.116
-
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
Score: 0.114
-
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
Score: 0.114
-
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
Score: 0.108
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.106
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.105
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
Score: 0.104
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.100
-
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016 Jun; 24(6):1135-1149.
Score: 0.098
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.084
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.053
-
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31.
Score: 0.048
-
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41.
Score: 0.047
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
Score: 0.044
-
Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
Score: 0.043
-
Targeting glycans for CAR therapy: The advent of sweet CARs. Mol Ther. 2022 09 07; 30(9):2881-2890.
Score: 0.038
-
Cancer vaccines. Hematol Oncol Clin North Am. 2001 Aug; 15(4):741-73.
Score: 0.036
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.033
-
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells. Sci Adv. 2020 07; 6(27):eaaz7809.
Score: 0.033
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.027
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.027
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.027
-
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
Score: 0.027
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.025
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.023
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.023
-
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9.
Score: 0.021
-
T cell V-gene usage in man in some normal and abnormal situations. Ann N Y Acad Sci. 1991 Dec 30; 636:9-19.
Score: 0.018
-
Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
Score: 0.018
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.017
-
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60.
Score: 0.016
-
Surface expression of only gamma delta and/or alpha beta T cell receptor heterodimers by cells with four (alpha, beta, gamma, delta) functional receptor chains. J Exp Med. 1988 Sep 01; 168(3):1003-20.
Score: 0.015